Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised trial of the long term clinical effects of raising HDL cholesterol with extended release niacin/laropiprant

Next Previous
X
Search
Trial Profile

A randomised trial of the long term clinical effects of raising HDL cholesterol with extended release niacin/laropiprant

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Niacin/laropiprant (Primary) ; Ezetimibe/simvastatin; Simvastatin
  • Indications Cardiovascular disorders; Dyslipidaemias; Myocardial infarction; Stroke
  • Focus Therapeutic Use
  • Acronyms HPS2-THRIVE

    • Most Recent Events

    • 22 Aug 2019 Results exploring the safety profile of niacin-laropiprant and examining whether any patients were at lower (or higher) risk of its adverse effects published in the Clinical Therapeutics
    • 25 Mar 2013 Adverse events of this trial are reported to be consistent with those in the AIM-HIGH trial (niacin extended-release monotherapy), according to the University of Oxford media release.
    • 11 Mar 2013 Results presented at the 62nd Annual Scientific Session of the American College of Cardiology. Additional information taken from slides presented at the conference.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top